- Home
- ICLK vs FGEN Comparison
ICLK vs FGEN Comparison
Compare ICLK & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLK
- FGEN
- Stock Information
- Founded
- ICLK 2009
- FGEN 1993
- Country
- ICLK Hong Kong
- FGEN United States
- Employees
- ICLK N/A
- FGEN N/A
- Industry
- ICLK Computer Software: Prepackaged Software
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ICLK Technology
- FGEN Health Care
- Exchange
- ICLK Nasdaq
- FGEN Nasdaq
- Market Cap
- ICLK 29.1M
- FGEN 34.0M
- IPO Year
- ICLK 2017
- FGEN 2014
- Fundamental
- Price
- ICLK $3.13
- FGEN $0.36
- Analyst Decision
- ICLK
- FGEN
- Analyst Count
- ICLK 0
- FGEN 0
- Target Price
- ICLK N/A
- FGEN N/A
- AVG Volume (30 Days)
- ICLK 24.9K
- FGEN 1.5M
- Earning Date
- ICLK 12-11-2024
- FGEN 11-12-2024
- Dividend Yield
- ICLK N/A
- FGEN N/A
- EPS Growth
- ICLK N/A
- FGEN N/A
- EPS
- ICLK N/A
- FGEN N/A
- Revenue
- ICLK $133,217,000.00
- FGEN $180,015,000.00
- Revenue This Year
- ICLK $26.49
- FGEN $20.42
- Revenue Next Year
- ICLK $12.11
- FGEN N/A
- P/E Ratio
- ICLK N/A
- FGEN N/A
- Revenue Growth
- ICLK N/A
- FGEN 16.15
- 52 Week Low
- ICLK $1.03
- FGEN $0.18
- 52 Week High
- ICLK $4.01
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- ICLK 47.28
- FGEN 50.21
- Support Level
- ICLK $3.05
- FGEN $0.18
- Resistance Level
- ICLK $3.20
- FGEN $0.43
- Average True Range (ATR)
- ICLK 0.13
- FGEN 0.04
- MACD
- ICLK -0.02
- FGEN 0.01
- Stochastic Oscillator
- ICLK 29.27
- FGEN 66.94
About ICLK iClick Interactive Asia Group Limited
iClick Interactive Asia Group Ltd is an enterprise and marketing cloud Platform in China. It offers a consumer full lifecycle solution that addresses client's needs from traffic acquisition, customer relations management, and business decision optimization driven by data analytics in the retail era. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives the majority revenue from Mainland China and also has a presence in Hong Kong and other countries.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.